Literature DB >> 14529792

A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostate.

Robert A Price1, Scott Murphy, Shawn W McNeeley, C-M Charlie Ma, Eric Horwitz, Benjamin Movsas, Adam Raben, Alan Pollack.   

Abstract

PURPOSE: The focus of this work is to develop a practical planning method that results in increased dose conformity and reduced treatment time for segmental multileaf collimation (sMLC) based intensity-modulated radiation therapy (IMRT) delivery. METHODS AND MATERIALS: Additional regions for dose constraint are introduced within the normal tissue during the planning process by designing a series of concentric ellipsoids around the target. A dose gradient is then defined by assigning dose constraints to each concentric region. The technique was tested at two centers and data for 26 and 10 patients, respectively, are presented allowing for differences in treatment technique, beam energy, ellipsoid definition, and prescription dose. At both centers, a series of patients previously treated for prostate cancer with IMRT were selected, and comparisons were made between the original and new plans.
RESULTS: While meeting target dose specifications and normal tissue constraints, the average number of beam directions decreased by 1.6 with a standard error (SE) of 0.1. The average time for delivery at center 1 decreased by 29.0% with an SE of 2.0%, decreasing from 17.5 min to 12.3 min. The average time for delivery at center 2 decreased by 29.9% with an SE of 3.8%, decreasing from 11 min to 7.7 min. The amount of nontarget tissue receiving D(100) decreased by 15.7% with an SE of 2.4%. Nontarget tissue receiving D(95), D(90), and D(50) decreased by 16.3, 15.1, and 19.5%, respectively, with SE values of approximately 2% at center 1. Corresponding values for D(100), D(95), D(90), and D(50) decreased by 13.5, 16.7, 17.1, and 5.1%, respectively, with SE values of less than 3% at center 2.
CONCLUSION: By designating subsets of tissue as concentric regions around the target(s) and carefully defining each region's dose constraints, we have gained an increased measure of control over the region outside the target boundaries. This increased control manifests as two distinct endpoints that are beneficial to the IMRT process: increased dose conformity and decreased treatment time.

Entities:  

Mesh:

Year:  2003        PMID: 14529792     DOI: 10.1016/s0360-3016(03)00711-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer.

Authors:  Tracy L Klayton; Karen Ruth; Eric M Horwitz; Robert G Uzzo; Alexander Kutikov; David Y T Chen; Mark Sobczak; Mark K Buyyounouski
Journal:  Radiother Oncol       Date:  2011-08-31       Impact factor: 6.280

2.  Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer.

Authors:  Lora S Wang; Colin T Murphy; Karen Ruth; Nicholas G Zaorsky; Marc C Smaldone; Mark L Sobczak; Alexander Kutikov; Rosalia Viterbo; Eric M Horwitz
Journal:  Cancer       Date:  2015-05-29       Impact factor: 6.860

3.  Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer.

Authors:  Yanqun Dong; Nicholas G Zaorsky; Tianyu Li; Thomas M Churilla; Rosalia Viterbo; Mark L Sobczak; Marc C Smaldone; David Yt Chen; Robert G Uzzo; Mark A Hallman; Eric M Horwitz
Journal:  J Med Imaging Radiat Oncol       Date:  2017-10-13       Impact factor: 1.735

4.  Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.

Authors:  Alan Pollack; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Andre A Konski; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; C-M Charlie Ma; Shawn W McNeeley; Mark K Buyyounouski; Robert A Price
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-19       Impact factor: 7.038

5.  Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratification method.

Authors:  Nicholas G Zaorsky; Tianyu Li; Karthik Devarajan; Eric M Horwitz; Mark K Buyyounouski
Journal:  Cancer       Date:  2012-04-27       Impact factor: 6.860

6.  PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition.

Authors:  Tracy L Klayton; Karen Ruth; Mark K Buyyounouski; Robert G Uzzo; Yu-Ning Wong; David Y T Chen; Mark Sobczak; Ruth Peter; Eric M Horwitz
Journal:  Pract Radiat Oncol       Date:  2011

7.  Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Navesh K Sharma; Tianyu Li; David Y Chen; Alan Pollack; Eric M Horwitz; Mark K Buyyounouski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-01       Impact factor: 7.038

8.  How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?

Authors:  David J D'Ambrosio; Karen Ruth; Eric M Horwitz; Robert G Uzzo; Alan Pollack; Mark K Buyyounouski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

9.  Does treatment duration affect outcome after radiotherapy for prostate cancer?

Authors:  David J D'Ambrosio; Tianyu Li; Eric M Horwitz; David Y T Chen; Alan Pollack; Mark K Buyyounouski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-09       Impact factor: 7.038

10.  Treatments of exceptionally large prostate cancer patients with low-energy intensity-modulated photons.

Authors:  Mei Sun; Lijun Ma
Journal:  J Appl Clin Med Phys       Date:  2006-11-28       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.